Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1
The goal of this clinical trial is to assess how the location of local anesthetic medication affects pain control capabilities in adult patients undergoing thoracic(chest)-only minimally invasive surgery. The main questions it aims to answer are: * Is pain decreased when local analgesia is provided as a combination of serratus anterior plane block and intercostal nerve block when compared to either block administered individually? * How does location of local analgesia administration impact length-of-stay, cost-of-care, and quality-of-life? Researchers will compare three treatment options including long-acting local anesthetic (Exparel®) administered as (1) intercostal nerve block, (2) serratus anterior plane block, or (3) combination of intercostal nerve block and serratus anterior plane block to see if pain and opioid use are reduced dependent upon treatment group. All participants will receive a local anesthetic nerve block. Participants will be asked to describe their pain after surgery and to answer various questionnaires before and after surgery.
Checked against the public recordLast updated Aug 26, 2026 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Not applicable
- Sponsor
- University of Texas Southwestern Medical Center
- Interventions being studied
- Procedure: Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block; Procedure: Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block; Procedure: Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
Inclusion Criteria: * Plan to undergo planned (elective) minimally invasive isolated R-VATS procedure, to include pulmonary anatomic resections (anatomic lobectomy, segmentectomy, and wedge resection if performed robotically) * Age ≥ 18 years old * Ability to understand and capacity/willingness to sign a written informed consent form Exclusion Criteria: * Age \< 18 years old * Unwilling to sign informed consent form, mentally challenged/delayed, or lacking capacity/unable to consent to participation in the trial own their own behalf * Vulnerable populations * Incarcerated individuals * Pregnant individuals * Breastfeeding individuals * Individuals with potentially altered pharmacokinetics and metabolism of study drugs * Renal failure: creatinine ≥ 2, or glomerular filtration rate \< 45 mL/min * Hepatic failure: serum ammonia \> 33 mcg/dL and/or Child-Pugh \> A * Individuals suffering from chronic pain * Individuals taking pre-operative narcotics * Patients undergoing emergent surgery or urgent surgery for acute, traumatic injuries * Patients undergoing extra-pleural resections, chest wall resection, pleurectomies, pleurodesis, and decortications * Planned concurrent abdominal procedure: for example, but not limited to, an esophagectomy * Patients requiring subcostal transversus abdominis plane (TAP) block * Use of a rib spreader during thoracic procedure * Patients admitted to the intensive care unit (ICU) post-operatively while sedated and intubated * Patients with major post-operative complications * Wedge resection for pulmonary bleb * Unanticipated pleurectomy, even if partial * Surgeon injects superficial wounds with LipoB
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Clements University Hospital at University of Texas Southwestern Medical CenterDallas, Texas
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Aug 26, 2026. Always confirm current availability with the study team.